OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
FDA Expands Cancer Treatment Options with New Drug Approvals

FDA Expands Cancer Treatment Options with New Drug Approvals

by FDA Approval | 15 August 2024 | Solid Tumors, Women's Cancers

The U.S. Food and Drug Administration (FDA) has recently expanded its indications and granted approvals for three drugs, offering new options for patients with various forms of cancer. The approved drugs—dostarlimab-gxly for endometrial cancer, afamitresgene...
FDA Approves Repotrectinib for Patients with NTRK Gene Fusion-Positive Solid Tumors

FDA Approves Repotrectinib for Patients with NTRK Gene Fusion-Positive Solid Tumors

by FDA Approval | 14 June 2024 | Solid Tumors

The FDA has granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. This approval targets patients with locally...
FDA Approves Selpercatinib for RET Fusion-Positive Thyroid Cancer

FDA Approves Selpercatinib for RET Fusion-Positive Thyroid Cancer

by FDA Approval | 13 June 2024 | Solid Tumors

The FDA has approved selpercatinib for both adults and pediatric patients who are 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. This approval comes...

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}